DANISH HEALTHCARE BUSINESS

덴마크 헬스케어 비즈니스

DANISH HEALTHCARE BUSINESS

Headed by the Danish Minister for Health and Prevention

Seoul, 27 August 2013

2013년 8월 27일 서울 신라호텔에서 주한덴마크대사관과 덴마크 복지부가 공동주

최한 덴마크 헬스케어 기업세미나가 개최되었습니다.

한국과 덴마크 양국의 헬스케어산업 분야 협력 관계를 발전시키기 위한 자리가 마

련되어, 한국과 덴마크의 주요인사를 비롯해 100여명에 달하는 관계자들이 참석해

양국의 헬스케어 분야 협력에 대해 높은 관심을 나타내었습니다.

이날 오전에 개최된 기업 세미나에서는 노보노디스크, 룬드벡, 레오파마 등 덴마크

에 본사를 둔 다국적기업 10곳이 소개되어 양국의 의료·제약산업에 대한 정보 교

환도 이뤄졌습니다.

이에 추가적으로 덴마크 헬스케어 비즈니스 사절단에 관한 자료(덴마크의 보건의

료 분야에서 혁신과 연구 개발에 앞서는 업체 소개)를 게재합니다.

목 차 (Table of Contents)

1. Falck (팔크)...........................................................................................................................................08

2. LEO Pharma (레오파마)..................................................................................................................10

3. Lundbeck (룬드벡)............................................................................................................................12

4. MedTech Innovation Center (메디테크 이노베이션 센터)............................................14

5. Novo Nordisk (노보 노디스크)...................................................................................................16

6. Radiometer (라디오메터)...............................................................................................................18

7. Statens Serum Insititut (스타텐스 세럼 인스티튜트).......................................................20

8. Central Denmark Region A (센트럴 덴마크 지역 A)......................................................22

9. Central Denmark Region B (센트럴 덴마크 지역B).........................................................24

10. North Denmark Region (북부 덴마크 지역).....................................................................26

11. New North Zealand Hospital (노쓰 질랜드 신병원).....................................................28

12. Zealand Region (질랜드 지역).................................................................................................30

13. Royal Danish Embassy, Seoul (주한 덴마크 대사관 소개)........................................32

Falck's activities are directed at preventing accidents and disease; providing assistance in situations of emergency, accidents and need ; and helping people move on with their lives after illness or accidents.

Falck is a Nordic based organisation with business activities in 36 countries on five continents. The organisation primarily offers these services:

All these services are built on a fundamental vision that Falck consists of people helping people. Falck's employees respond when there is a fire; they train people in taking care of themselves and the people around them; they fix cars that won t run and they relieve pain of the body and soul. Thus, empathy and determination is part of all Falck employees DNA.

Emergency Medical Services

Patient Transportation

Medical Clinics and Doctors On-Call

Occupational Health

International Medical Assistance

Health Care Temp Services

Fire Services

Oil, Gas and Mining Safety Services

Risk Management

Roadside Assistance

Home Safety

FALCK

8

(Falck)

35

.

,

,

. .

FALCK

Mr. Allan Søgaard Larsen CEO

e-mail: [email protected] tel: +45 7033 3311

http://www.falck.com/9

LEO Pharma is an independent, research-based pharmaceutical company founded in 1908.LEO Pharma helps people achieve healthy skin by delivering care solutions that empower people to better manage their skin conditions and live confidently. The company develops, manufactures and markets pharmaceutical drugs to dermatologic and also thrombotic patients in more than 100 countries. LEO Pharma has its own sales forces in 61 countries and employs 4,800 employees worldwide. The company is headquartered in Denmark and owned by the LEO Foundation. Mission & Vision

Our missionWe help people achieve healthy skin. Our visionWe are the preferred dermatology care partner improving people's lives around the world. Organisation

To live the mission and realise the vision, LEO Pharma is expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs. The organisation is scalable and flexible and givesroom and opportunity for cross-disciplinary collaboration across the entire company. The company focuses on sharing of knowledge, ideas and skills and pursuit of innovative approaches, adaptation of new technologies and new conditions. The LEO Foundation

LEO Pharma is owned in full by the LEO Foundation. The foundation was created in 1984 with an overall objective of ensuring that LEO Pharma, now and in the future, is a significant and responsible player in the research, development and marketing of care solutions - to the benefit of patients around the world and the company's own continued development. The long-term owner perspective of the LEO Foundation is the reason why LEO Pharma has been able to evolve into a world leader in research, development and marketing of pharmaceuticals for the treatment of skin diseases. The LEO Foundation is unique among its peers as it maintains total independence of outside interests. No family members, external shareholders or others receive support or dividends.

LEO PHARMA A/S

10

Mr. Lars Olsen Executive Vice President


http://www.leo-pharma.com/

LEO PHARMA A/S

(LEO Pharma) 1908 ,

.

100 ,

.

61 4,800 .

(LEO Foundation) .

&

.

,

.

.

.

.

, , ,

.

1984 , , ,

.

,

.

.

.

11

H. Lundbeck A/S is known worldwide for its pioneering efforts in the fields of psychiatry and neurology, and is the only fully integrated pharmaceutical company in the world that focuses entirely on discovering new and effective therapies for treatment of central nervous system disorders.

Among the first to provide treatments for disorders such as schizophrenia and depression more than 50 years ago, Lundbeck continues its dedication to forward-looking research and development, employing cutting-edge research and utilizing the latest in product development technologies. It is Lundbeck's mission to improve the lives of people who have psychiatric or neurological disorders by working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others. Lundbeck currently has advanced research and development projects in depression, schizophrenia, epilepsy, psychosis, stroke and Alzheimer's disease. Lundbeck invests more than 20% of its revenue in research and development. Lundbeck worldwide

While Lundbeck's origins are in Denmark, our drugs are available in more than 100 markets, and around 5,800 employees in 57 countries represent the company. Lundbeck research facilities are located in Denmark, the US and China, while production facilities are based in Denmark, France, Italy, Mexico and China. Lundbeck's most recently launched compounds include Cipralex/Lexapro (depression), Ebixa (Alzheimer's disease), Azilect (Parkinson s disease), Xenazine (chorea associated with Huntington's disease), Sabril (epilepsy), Sycrest /Saphris (bipolar disorder), Onfi (Lennox-Gastaut syndrome), Abilify Maintena (schizophrenia) and Selincro (alcohol dependence).

H. LUNDBECK A/S

12

(H. Lundbeck A/S)

.

50 , ,

.

.

.

, .

, , , ,

. 20% .

100 57 5,800

. , ,

, , , , .

Cipralex/Lexapro ( ), Ebixa ( ), Azilect (

), Xenazine ( ), Sabril ( ), Sycrest /Saphris ( ),

Onfi ( ), Abilify Maintena ( ), Selincro (

) .

Mr. Ole Chrintz Senior Vice President


http://www.lundbeck.com/global

H. LUNDBECK A/S

13

MedTech Innovation Center (MTIC) is an accelerator providing business and product development support for companies and hospitals in the Central Denmark Region. MTIC helps Danish companies develop new innovative products for the healthcare sector globally.

MTIC supports companies primarily within health IT, medical device, assisted living and home care sectors.

Recently, MTIC has initiated the Biomedical Design education in Denmark, modeled after - and in collaboration with - Biodesign at University of Stanford, California, US. This education will focus on developing healthcare products based on realized and commercially relevant clinical needs. Biomedical Design is initialized together with Aarhus University and the University Hospital in Aarhus, and with a number of international partners.

http://www.mtic.dk

http://bioxdenmark.au.dk

MEDTECH INNOVATION CENTER

14

(MedTech Innovation Center)

.

. , ,

.

.

.

.

http://www.mtic.dk

http://bioxdenmark.au.dk

Ms. Trine Winterø CEO


http://www.mtic.dk/en

MEDTECH INNOVATION CENTER

15

A passion for helping people Novo Nordisk was founded in 1923 in Denmark, the same year when insulin was first introduced as a product to Scandinavia from a passion for helping people by August Krogh, a Nobel Prize-winning professor at the University of Copenhagen, and his wife, Marie Krogh, who was seeing her patients with type 1 diabetes as a doctor and having type 2 diabetes herself. Our founders began a journey to change diabetes. Today, we are thousands of employees across the world with the passion, the skills and the commitment to continue this journey to prevent, treat and ultimately cure diabetes. Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. There are approximately 1,100 employees in Japan & Korea. Our business philosophyThe Triple Bottom Line - our way of doing business We believe that a healthy economy, environment and society are fundamental to long-term business success. This is why we manage our business in accordance with the Triple Bottom Line business principle and pursue business solutions that maximise value to our stakeholders as well as our shareholders. In practice, this means that any decision should always seek to combine three considerations: is it financially, socially and environmentally responsible? This way, we continuously optimise our business performance and enhance our contribution to the societies we operate in.

NOVO NORDISK

16

(Novo Nordisk) 1923 ,

(August Krogh) 2 1

(Marie Krogh) .

1923 , .

, .

90

. , ,

.

75 35,000 180

, 1,100 .

(Triple Bottom Line)

, ,

, ,

.

, ,

.

Mr. Claus Eilersen Senior Vice President


http://www.novonordisk.com/

NOVO NORDISK

17

Radiometer was founded in 1935 by Danish engineers Carl Johan Schrøder and Børge Aagaard Nielsen. Originally the company manufactured electronic measuring instruments for the growing radio industry, hence the name Radiometer. In 1952 Denmark was afflicted by a serious polio epidemic, and many children died of respiratory failure. In cooperation with two doctors, Radiometer developed an instrument for measuring the pH value of blood, which was the key to making the right diagnosis. In 1954 Radiometer launched the first blood gas measuring instrument, the Astrup Apparatus, for determining the acid-base balance in blood. This changed Radiometer s path forever. In the following years Radiometer continued developing and refining their blood gas analyzer, extending the number of parameters measured and automating the analysis process. At regular intervals a new generation of blood gas analyzers was launched giving Radiometer a leading position on the market worldwide. In 2008 Radiometer took a leap from the blood gas market to the much larger acute care market by launching the AQT90 FLEX analyzer measuringcardiac, coagulation, infection and pregnancy markers. Today Radiometer is a leading provider of technologically advanced acute care solutions that simplify and automate all phases of acute care testing. Radiometer offers solutions for blood gas analysis, transcutaneous monitoring and immunoassay testing, where quick response timesare of the utmost importance. By providing fast and accurate acute diagnostic results, healthcare professionals can make immediate and well-informed decisions that enable them to improve patient care and optimize patient flow in all acute care settings - intensive care units (ICUs), emergency departments (EDs) and operating rooms (ORs). Radiometer's products and services are available in more than 100 countries around the world through wholly-owned subsidiaries and approved distributors. Radiometer has 2,365 employees, 948 in Denmark and 1,417 abroad. Radiometer is part of the US-based Danaher Corporation with approximately 63,000 employees distributed across five different business segments and operating in more than 125 countries worldwide (NYSE:DHR).

RADIOMETER

18

(Radiometer) 1935 ,

(Carl Johan Schr der)

(B rge Aagaard Nielsen) .

.

1952 ,

,

pH .

1954 (Astrup Apparatus)

.

.

.

2008 , , , AQT90 FLEX

.

. , ,

.

,

(ICU), (ED), (OR)

.

100

. 2,365 1,417 .

(Danaher Corporation) .

63,000 125 .

Ms. Lyn Bourke Asia Pacific Director


http://www.radiometer.com

RADIOMETER

19

STATENS SERUM INSTITUT

National Health Institute of DenmarkStatens Serum Institut (SSI) is a publicenterprise under the Danish Ministry of Health. For more than 110 years, SSI s main task has been to secure the preparedness towards infectious diseases and congenital disorders. The tasks have been expanded, and today, SSI is an international research, production and service enterprise.

SSI is responsible for research-based prevention and control of infectious diseases, biological threats and congenital disorders. SSI performs the health surveillance and secures the rational use of IT in the Danish healthcare system. SSI produces vaccines and biological products that are exported to more than 100 countries in the world

SSI's tasks include:

Mission and Tasks

Key FiguresSSI has 1,300 full-time employees and a net revenue of DKK 1,443m/EUR 193m. Export is DKK 374m/EUR 50m and rising due to sales of vaccines, biological products, technology and IPR.SSI produces approximately 50 million doses of vaccines yearly (BCG-, Diphtheria-, Tetanus-, Polio-(IPV) and acellular Pertussis-vaccines). The production of biological products includes Tuberculin and diagnostic sera (Pneumococcal-, E.coli- and Salmonella-sera).

Research and development is vital for the fulfilment of SSI's purpose, and the Institute has world leading research in epidemiology, microbiology, genetics and vaccines. Each year SSI uses more than 10% of the revenue on research and development, resulting in 400 international scientific papers and in new patents (IPR).

Surveillance and control of infectious diseases and congenital disorders.Reference laboratories for infectious, autoimmune, congenital and genetic diseases.Ensuring the supply of vaccines, other biological products and diagnostic services through production and procurement. Preparedness against biological terrorism. Collection and communication of data concerning the health status of the Danish population, including financial and quality control data of the Danish healthcare system.Ensuring national frameworks and standards for e-Health in the Danish healthcare system and managing and developing IT systems for the Danish Ministry of Health.SSI aims to ensure advanced control of infectious diseases, including new infections and biological threats.Research and development in the Institute s areas of activity at an international level.

20

(Statens Serum Institut (SSI)) , 110

.

, .

, .

. 100 .

:

.

, , , .

, .

.

.

e-Health

.

.

.

1,300 14 ( 2 )

. 3 (5 ) , ,

IPR . 5 (BCG-,

Diphtheria-, Tetanus-, Polio-(IPV) acellular Pertussis- ) .

Tuberculin (Pneumococcal-, E.coli- Salmonella- ) .

, , , .

10%

, 400 (IPR)

.

Mr. Nils Strandberg Pedersen President


http://www.ssi.dk

STATENS SERUM INSTITUT

21

Central Denmark RegionCentral Denmark Region is one of the five regions in Denmark. The region covers the central part of the peninsula of Jutland. It is geographically the largest region in Denmark and has a population of 1.2 million. The region consists of 19 municipalities and several large cities, including Denmark s second-largest city, Aarhus, with approx. 300,000 inhabitants. The region is primarily responsible for the health sector including hospitals and general practitioners, but also the social care and psychiatry sectors. Also, the area of Regional Development covering business, education, culture, natural resources, energy, environment and public transportation is a responsibility of the region.

OrganisationThe Regional Council consists of 41 elected politicians. Present members were elected November 17th 2009. The next election will be on November 19th 2013.Corporate Management - consists of the Region Chief Executive and two Head of Corporate Management. EconomyThe region is financed by the state and the municipalities. Part of the region expenditure is financed through a block grant, whereas other subsidies are locally and activity-related. The state block grant constitutes the most significant element of financing - approx. 70%. Central Denmark Region has a budget of 28 billion DKK (5 billion USD).

HealthThe primary responsibility of Central Denmark Region is public healthcare including tasks as operation of regional hospitals, general practitioners and practising specialists. Another task within healthcare is the organisation of the emergency medical service, including ambulance and emergency physician services. Central Denmark Region also has research, developmental and training commitments, as well as shared assignments and collaboration with municipal authorities.The area of health constitutes the largest of Central Denmark Region's field of activity. Approximately 20.000 doctors, nurses and other health care professionals are employed at the 10 regional hospitals.

Psychiatry and social serviceThe region provides psychiatric services for children, adolescent and adults suffering from mental illness. The services cover the inpatient management, acute and intensive care, diagnosis and treatment. Within the area of social services, the region in agreement with the local municipalities operates a range of specialised services and institutions for groups with special needs for social services and special education.

Regional DevelopmentThe department of Regional Development is responsible for the Regional Development plan and the Business development Strategy.

CENTRAL DENMARK REGION

22

(Central Denmark Region) 5

(Jutland)

. 120

.

(Aarhus- 300,000 ) 19

.

. , , ,

, ,

.

(The Regional Council) 41

. 2009 11 17 , 2013 11 19

.

(Corporate Management) 2 .

.

, .

, 70% . 280 (DKK)

. ($50 USD)

, ,

.

.

,

. . , 20,000

10 .

, ,

. , , , .

,

, .

(Regional Development)

.


Mr. Ole Thomsen Head of Corporate Management

e-mail: [email protected] tel: 45 7841 0040 http://www.rm.dk

23

Regional Hospital West Jutland - a part of Central Denmark Region

The hospital unit has its origins in five separate hospitals, which came under joint management in 2006. Since then the hospital unit has been completely reorganised, with a redistribution of departments and staff within and across the 5 hospitals. This means that although the hospital still has activities across multiple locations it now operates as one fully integrated hospital unit.

Currently it serves a population of 285-500.000 depending on the medical specialty. The hospital has 440 beds, 50.000 admissions per year and an average admittance of 2.9 days. In 2013 it will receive 300.000 outpatient visits.

In 2009 it was announced, that a new hospital is to be built to collect all departments under one roof. Since then this process has only intensified.

When finished in 2019, the new 135.000 sq. meter hospital will be at the pinnacle of heath care solutions in Denmark. It will have 460 beds, 48.000 annual admissions and 385.000 outpatient visits per year.

The planning of the new hospital has highlighted the shared culture of the existing hospital unit. A massive investment in employee involvement has revealed common needs and has prompted innovative approaches to cooperation between departments.

It has lead to a synergetic approach to the treatment of our patients - not merely as cases for singular highly specialized medical professions - but as the centre of a process, where the needs of the individual patient activates the many fields of expertise the hospital has to offer.

The structure of the planned buildings and the organisation, reflects this change, so that Regional Hospital West Jutland can truly fulfill its vision of becoming the patient's hospital.

A highly efficient, competitive and quality conscious hospital in which patients, their families and the employees of the hospital can thrive.


24

-

2006 , .

.

285 , 500,000

. 440 50,000

2.9 . 2013 300,000 .

2009 5

.

2019 135,000 ,

. 460 , 48,000 385,000

.

.

,

.

.

, ,

.

,

, ,

.

Mr. Henning Kurt Vestergaard Hospital CEO


http://www.vest.rm.dk/forside


25

The North Denmark Region is one of five regions in Denmark. With its 578,839 citizens, the region is the smallest as regards population. It consists of eleven municipalities. The budget of the North Denmark Region is approximately 10.9 billion DKR ( 1.46 billion). 14.500 people are employed in the region, and over 90% of them are working in the Health Care Sector Health Care which includes hospitals, psychiatry and the primary sector. The hospitals in Northern Denmark represent practically all medical specialities, and offer most types of treatments. The psychiatry in the North Denmark Region offers various treatments for citizens with severe mental disorders, who need a more specialised treatment. The Primary Sector ensures free health care from general practitioners as well as specialists. Subsidies are also provided for medicine and for treatments by dentists, physiotherapists, chiropodists, chiropractors and psychologists. In Regional Development Sector the main objective is to enhance growth and development in the North Denmark Region. The North Denmark Region is also responsible for providing social services and specialised education for people who need physical and mental assistance and development.

Strategic focus on Health Care Improvement, eHealth and mHealth Health care improvement, public-private partnerships and health & hospital innovations are of high priority for The North Denmark Region. We collaborate with a number of partners - both public and private - on becoming a large-scale experimentarium for eHealth and telemedicine, especially regarding telehomecare and the treatment of Chronic obstructive pulmonary disease (COPD), Currently we are implementing TeleCare Nord, a R&D/ pilot program to a full scale demonstration project.

NORTH DENMARK REGION

The North Denmark Region is responsible for three main tasks.

26

. 578,839

11 . 109

(DKK - 15 ) . 14,500 90%

.

,

.

.

. , , ,

, .

/

.

, e-Health, m-Health

, - , .

e-Health , (COPD)

. TeleCare

Nord .

Ms. Dorte Maarbjerg Stigaard Director


http://www.rn.dk/Regionen/English/

NORTH DENMARK REGION

27

NEW NORTH ZEALAND HOSPITAL

In June 2011 the Regional Council decided to merge three hospitals currently located in Northern Zealand and combine them in a new acute hospital in Hiller d (scheduled to open in late 2020): New North Zealand Hospital. Building a brand new hospital on pristine land is a once in a lifetime opportunity - but also an obligation. This project expects us to be innovative, to build for the future and for patients, patient families and staff, without any trammels. But it also commits us - we must learn from the world around us and there must be room for things that haven't even been invented yet. It represents a shift in paradigm both due to the single patient rooms and due to the increasing number of out patients. At present, the line between hospital and home is no longer a clear-cut. Technology provides new opportunities, which means that treatment does not necessarily need to take place in the hospital. Patient empowerment and patient education are issues to be aware of. Remember Customers first in every solution. We have within the last year employed specialists in areas of logistics, hospital planning and engineering to strengthen the organisation. We have high ambitions and aim for the best innovative solutions for the new hospital by analysing the demands with a professionally approach. We seek inspiration and learning's from all over the world both within the healthcare and private sector. With the knowledge share we wish to have a functional, interesting architecture, visionary solutions and effective logistics. Our goal is to set new standards for future health care design in every way. Facts about New North Zealand Hospital:

The hospital will include an emergency department and cover 24 medical specialties.The hospital will serve as an acute district hospital for more than 310.000 citizens in Northern Zealand and will have about 662 beds in single patient roomsThe total floor areawill be approximately 124,000 m2Total construction sum will be DKK 4 billion(app. 700 million dollars)The hospital will employ approximately 3500 peopleThe competition for the design of a masterplan has been launched. The final winner will be selected in March 2014.

Links:Homepage: Facebook: Competition brief: (open with Firefox, Google Chrome or Safari)

http://www.regionh.dk/nythospitalnordsjaelland/menuhttps://www.facebook.com/nythospitalnordsjaelland

http://www.regionh.dk/nhn/brief

28

2011 6 , (Northern Zealand) 3

, 2020 (Hiller d)

(New North Zealand hospital) .

. , ,

. .

.

.

, . .

.

. ,

.

, , .

.

, .

, .

.

:

24 .

(Northern Zealand) 310,000 662

1 . 2 124,000 m .

3,500 .

2014 3 .

(open with Firefox, Google Chrome or Safari)

http://www.regionh.dk/nythospitalnordsjaelland/menu

https://www.facebook.com/nythospitalnordsjaelland

http://www.regionh.dk/nhn/brief

NEW NORTH ZEALAND HOSPITAL

Mr. Henrik Sch dts Vice President

e-mail: [email protected]: +45 3143 2041

http://www.nythospitalnordsjaelland.dk

29

Region Zealand has an annual turnover of approx. 2,3 billion Euros and has approx. 17.000 employees. The Region operates primarily within the health sector, including running hospitals. Region Zealand is also responsible for regional growth and development strategies as well as public transport (regional busses and local railways). Region Zealand also plays a central role in a network of cooperating partners, who work for a dynamic and coordinated development throughout the region, i.a. for business, education, urban development and certain environmental areas. Most of the employees work within the health care system and in the psychiatric units, or help children and adults in highly specialised social institutions. The wide range of services is spread out across 17 municipalities in the Region. There are six somatic hospitals along with a variety of psychiatric services in the region and primary care facilities. Region Zealand is overseen by Regionsradet (The Regional Council) which consists of 41 politicians, who are publicly elected. Council meetings, which are open to the public, are held once a month. The tasks are carried out in a dynamic interaction between the various units of the organisation. Managers and heads of ten administrative areas and five cross disciplinary areas, along with the three members of the Executive Management, constitute the Corporate Management of Region Zealand. The regions in Denmark are not financed by imposing taxes, but rely entirely on central state funding (around 70%) and funding from the 17 municipalities (around 30%), according to a centrally marked out calculation model. The budget is spent on i.a. busses, trains, business development, environmental tasks and the running of social institutions. However, most of the budget is spent on hospitals, psychiatric units and other expenses, related to national health services.

ZEALAND REGION

30

23 , 17,000

. ,

.

, , ,

.

, .

17 6 , 1

.

41 ,

.

.

10 5 3 .

,

( 70% ) 17 ( 30% ) .

,

, , , .

Mr. Jens Andersen CEO


http://www.regionsjaelland.dk/sider/english.aspx

ZEALAND REGION

31

The Embassy of Denmark in the Republic of Korea represents Danish interests in Korea in a wide range of areas including political and commercial relations as well as cultural and consular matters.

Korean-Danish relations are based on longstanding friendship and mutual understanding. The State Visit of former President Lee Myung-bak to Denmark in May 2011 represented an important milestone in the development of these relations with the establishment of a strategic partnership encompassing the most significant areas of present and future cooperation between Denmark and Korea, including a unique Korean-Danish Green Growth Alliance.

Trade and investment is a cornerstone in Korean-Danish relations and one of the most important tasks of the Embassy. Danish exports to Korea amounted to approximately USD 770 million in 2012 representing an increase of 20 % year-on-year. An increasing number of Danish companies have established subsidiaries in Korea while others are active in Korea through local agents and distributors. While machineries, foodstuffs and pharmaceuticals have dominated Danish exports to Koreain past years, Danish competencies within environment technology and sustainable energy has seen some of the fastest growth since the establishment of the bilateral alliance.

The staff of the Embassy of Denmark provides tailored consultancy to companies, research institutionsand organizations that wish to enter or are already active in Korea.We work to ensure the best possible overall framework conditions for the Danish business and research community in Korea and it has expanded to include an Innovation Center aiming to strengthen commercially founded science, technology and innovation collaboration between Denmark and Korea.

You are always welcome to contact the Embassy for any information you may need.

EMBASSY OF DENMARK IN KOREA

32

, ,

.

. 2011 5 ,

. -

.

. 2012 770 20%

.

, , , .

.

,

.

, , ,

.

.

EMBASSY OF DENMARK IN KOREA

Namsong Building 5th floor260-199 Itaewon-dong, Yongsan-gu

Seoul 140-200, Republic of KoreaPhone: +82 2 795 4187 E-mail: [email protected]

Website: www.sydkorea.um.dk

33

www.sydkorea.um.dkFollow us on Facebook:www.facebook.com/ambseoul

DANISH HEALTHCARE BUSINESS

Documents

Transcript of DANISH HEALTHCARE BUSINESS